PosterSessionOnline

EUROPEAN MULTIDISCIPLINARY ON UROLOGICAL CANCERS..

15th European Multidisciplinary Congress on Urological Cancers (EMUC23)

02-05 November 2023 Marseille

N. Poster

Poster title

Applicant name

Status


P-001	Programmed death-ligand (PD-L1) immunoexpression and clinical outcomes in Penile Squamous Cell Carcinoma	Ines Peyroteo	Received

O-001	MRI in penile cancer: Correlating examination and histopathology with imaging	Mayank Gupta	Received

P-2	Saving More Than Just Skin: A Study of Penile Sparing Approaches in Cancer Treatment	George Shaker	Received

P-005	The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer	Maarten Donswijk	Received

O-008	Intense surveillance for patients treated with radical prostatectomy and adverse pathologic features: early results from easy-1 (early salvage radiotherapy-1) protocol	Martina Monti	Received

P-009	The probability of metastases within different Prostate-Specific Antigen (PSA) ranges using Prostate-Specific Membrane Antigen (PSMA) positron emission tomography in patients with newly diagnosed prostate cancer	Wietske Luining	Received

O-010	The 3 year follow-up of the CRIMI study	Marinka Remmelink	Received

O-011	Post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer at a national referral center	Panagiotis Vlachostergios	Received

O-12	Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial	Laura Hendrickson	Received

P-012	Telomere biology as a prognostic factor in radical prostatectomy	Juan Manuel Rubio Galisteo	Received

P-017	MRI/US fusion, transperineal prostate biopsy utilising electro-magnetic Vector needle tracking, under local anesthesia	Marta De Santis	Received

P-021	The value of PSMA-PET in Addition to mpMRI and Systematic Biopsies to Select Patients for Hemi-ablative Focal Therapy in Prostate Cancer	Matthijs Scheltema	Received

P-024	A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study	Nawaid Usmani	Received

P-032	Stereotactic prostate radiotherapy with or without androgen deprivation therapy: A phase III, multi-institutional randomized-controlled trial. The SPA trial	Vittorio Morelli	Received

P-035	Validation of diagnostic nomograms based on mass spectrometry-based urinary biomarkers to distinguish clinically significant prostate cancer: complementing MRI pathway	Ana Cristina Morillo Tejedor	Received

P-038	Local anaesthesia transperineal (LATP) biopsy of the prostate: a new era for prostate cancer diagnosis?	Paul Lim	Received

P-039	Using PSMA PET to Guide Prostate Biopsies and Stage Men at High-Risk of Prostate Cancer	Yves Bodar	Received

P-046	Salvage cryotherapy for prostate cancer	Duarte Brito	Received

P-049	10-year experience of whole gland cryoablation: analysis of biochemical recurrence	Alejandro Reviriego Barrús	Received

P-054	Toxicity results of a multicentre randomized phase 3, non-inferiority trial on moderate hypofractionated radiotherapy.	Valerie Fonteyne	Received

P-060	Minimizing neurovascular bundle dose while maintaining target coverage in prostate radiotherapy	Victor Brand	Received

P-064	Real-World Treatment and Outcomes in Localized Prostate Cancer	Jose M. Calderon	Received

P-065	PSMA PET/CT in Biochemically Recurrent Prostate Cancer: multicenter external validation of a risk prediction nomogram	Laura Chamorro Castillo	Received

P-068	Serum levels of vitamin E (Vit E) in patients with proctitis after radical radiotherapy for localized prostate cancer	Geovana Marques Guimaraes	Received

P-069	PSA persistence after prostatectomy prognosis and the effect of adjuvant radiotherapy	Axel Möller	Received

P-071	The association between patient- and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance	Matthijs Duijn	Received

P-077	Baseline health-related quality of life as a prognostic indicator for survival in men with intermediate risk prostate cancer following radical prostatectomy	Thilo Westhofen	Received

P-081	Real World Utilisation of Androgen Deprivation Therapy Among Urology Practices: Characterising Initiation and Transition to Relugolix for Patients with Prostate Cancer (The REAL ADT Transitions Study)	Thierry Schulmann	Received

P-083	Post-metastasis survival in high-risk localised and locally advanced prostate cancer patients undergoing primary treatment in the United States: A retrospective study	Erin OBrien	Received

P-085	The optimal timing of ARAT administration against nmCRPC	Kazuhiro Matsumoto	Received

P-087	Acute toxicity results from a multicenter randomized phase 3 trial comparing external beam radiotherapy alone with external beam radiotherapy combined with brachytherapy in intermediate/high risk prostate cancer patients	Miranda Christianen	Received

P-088	Salvage radiotherapy after prostatectomy; trends and variation in Dutch clinical practice	Floor Staal	Received

P-093	Mutational profile of hormone-sensitive and castration-resistant metastatic prostate cancer	Clara Velasco Balanza	Received

P-096	Real-world data analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer: Are patients from RCTs the same from real life? Data from the European network of excellence for big data in prostate cancer (PIONEER).	Juan Gomez Rivas	Received

P-098	Real-world characterization of disease management and progression in metastatic and nonmetastatic castrate-resistant prostate cancer patients in Portugal: CaPA study	Catarina Leitao	Received

P-100	Apalutamide in Metastatic Prostate Cancer real life experience	Duarte Brito	Received

P-101	Treatment (tx) patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe	Melissa Kirker	Received

P-102	Matching-Adjusted Indirect Comparisons (MAICs) of Talazoparib versus Olaparib and Niraparib for First-line (1L) Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Melissa Kirker	Received

P-104	Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: Freedom from biochemical, radiological progression free survival and freedom from following treatment approaches within a randomized phase II trial (ARTO NCT03449719)	Giulio Francolini	Received

P-105	Is achieving undetectable PSA (uPSA) a prognostic factor for improved overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified treatments?	Jose M. Calderon	Received

P-106	The conundrum of treating metastatic hormone sensitive prostate cancer	Tessa van Elst	Received

P-107	A network meta-analysis on the safety of systemic treatments in metastatic hormone-sensitive prostate cancer patients	Irene Luccarini	Received

P-108	Expert consensus recommendations for managing adverse events in patients with metastatic prostate cancer treated with poly(ADP-ribose) polymerase inhibitor (PARPi) novel hormonal therapy (NHT) combination therapy	Hannah Dalglish	Received

P-109	An evaluation of service diversification in response to increasing therapeutic indications for 2nd generation hormone therapy in prostate cancer	Alicia Hague	Received

P-111	New or worsening type 2 diabetes mellitus (T2DM) in men treated with enzalutamide (ENZ) or abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): EVADE study	Anna George	Received

P-112	Analysis of prostate-specific antigen (PSA) kinetics in the third month of treatment with apalutamide in metastatic castration-sensitive prostate cancer (mCSPC)	Juan Luis Sanz Miguelañez	Received

P-114	The multicenter and randomized PROSFIT trial: Smart wearables to evaluate the impact of lifestyle changes in patients with metastatic hormone sensitive prostate cancer (mHSPC)	Teresa Alonso Gordoa	Received

P-116	Characteristics and healthcare resource utilisation (HRU) of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide (ENZ) or abiraterone acetate (AA) in England: PROCCO study	Anna George	Received

P-117	Retrospective Study to Describe Characteristics and Treatment Patterns of Patients with Metastatic Castration-resistant Prostates Cancer	Sahin Bahadir	Received

P-118	Real-world European study of treatment (tx) patterns in men with metastatic castration-resistant prostate cancer (mCRPC)	Melissa Kirker	Received

P-128	The influence of the prostate radiotherapy dose in the prediction of complete response in synchronous oligometastatic prostate cancer patients	Milo Gruji&263;	Received

P-129	Real-world data analysis of treatment outcomes for patients with metastatic hormone-sensitive prostate cancer: development of a survival prediction model. Results from the European network of excellence for big data in prostate cancer (PIONEER)	Juan Gomez Rivas	Received

P-132	Reliability and efficiency of the CAPRI-3 metastatic prostate cancer registry powered by artificial intelligence	Dianne Bosch	Received

P-133	Second line PSMA-targeted salvage treatment in patients with mi N1/M1a-b oligorecurrent PCa	Martina Monti	Received

P-135	Homologous recombination repair mutation (HRRm) testing patterns among men with metastatic castration-resistant prostate cancer (mCRPC): Results from a real-world (rw) study in Europe	Melissa Kirker	Received

P-139	Real-world (rw) homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in five European countries	Melissa Kirker	Received

P-140	Patient-reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) enzalutamide (ENZA) vs placebo (PBO) ENZA: Results from a phase 3 (TALAPRO-2) study	Saif Shaman	Received

P-144	COmplete ReSponse After systemic Immunotherapy /- Resection of residual disease in advanced ccRCC : the CORSAIR study	Philippe Boudier	Received

P-155	Factors affecting acute kidney injury and subsequent renal function recovery after robot-assisted partial nephrectomy for clinical T1a renal masses	Toshikazu Takeda	Received

P-156	Zanzalintinib (XL092) and nivolumab in nonclear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (NCT05678673)	Kim Nguyen	Received

P-160	Clinical characterisation, prognosis and assessment of predictive score for response to treatment of metastatic renal cells carcinoma with rhabdoid component	Louis Vallois	Received

P-166	Real-world outcomes of cabozantinib treatment after first-line checkpoint inhibitor-based combination therapy for patients with advanced renal cell carcinoma: CARINA study results	Lauren Reed	Received

P-168	Nivolumab as a treatment for metastatic renal cancer in second and successive lines. Experience at our hospital.	María Luisa Garrido Onecha	Received

P-172	Perioperative and long-term oncological outcomes after local tumor ablation for complex (PADUA Score =10) cT1a renal tumors: a multicenter analysis	Martina Monti	Received

P-174	The efficacy and safety of cone beam computed tomography for percutaneous renal cell carcinoma cryoablation: A single-center long-term follow-up study	Matthijs Duijn	Received

P-178	Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential ion for adjuvant therapy	Panagiotis Vlachostergios	Received

P-181	Proposal and internal validation of a nomogram for the prediction of local recurrence-free survival after percutaneous ablation for ct1 renal masses	Sara Tamburini	Received

P-184	Monitoring of pulmonary function by diffusing capacity of lung for carbon monoxide(DLCO) during BEP therapy for testicular cancer	Takeshi Kishida	Received

P-186	Overall Response rate with baby-BOP induction chemotherapy in patients with poor-risk, metastatic germ-cell tumors patients: A Retrospective Study in a Mexican hospital.	Miriam Alejandra Nájar Rodríguez	Received

P-211	Endoscopic ablation of UTUC in solitary kidney patients	Evangelia Papadimitriou	Received

P-212	Oncological outcomes of chemohyperthermia with HIVEC for BCG-unresponsive non-muscle invasive bladder cancer : results from a multicenter national database	Géraldine Pignot	Received

P-214	C-reactive protein is a prognostic factor after pembrolizumab for metastatic upper urothelial carcinoma	Hirotaka Nagasaka	Received

P-216	Neutrophil-to-eosinophil ratio (NER) predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma (aUC) enrolled in the MALVA study (Meet-URO 25)	ELISABETTA GAMBALE	Received

P-219	Evaluation of the use of postoperative single-shot instillation chemotherapy after TURBT and reasons for not administering it	Michal Fedorko	Received

P-224	Pembrolizumab Versus Atezolizumab in The Treatment of Advanced Urothelial Cancer: A Single Institution Experience	Nafie Makady	Received

P-225	A real word study of avelumab first-line maintenance in advanced urothelial carcinoma	Helena Guedes	Received

P-226	Delay of radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes	Sieb Nuijens	Received

P-228	Neoadjuvant versus adjuvant chemotherapy in muscle-invasive bladder cancer: The RealBLADDER study. Results on behalf of the GOIRC	ELISABETTA GAMBALE	Received

P-241	Atezolizumab as treatment of urothelial carcinoma in second line of metastatic disease. Experience in our institution.	Laura Lopez	Received

P-244	COVID-19 pandemic and non-muscle-invasive bladder cancer: impact on follow-up and disease recurrence	Frederico Portugal Gaspar	Received

P-251	Inhibitory coreceptors in variant histologies of bladder cancer the next chapter in urooncology?	Severin Rodler	Received

P-254	Prognostic factors for urachal carcinoma	Atsuto Suzuki	Received

P-256	Prognostic relevance of Platelet-to-Lymphocyte Ratio in patients with Muscle-Invasive Bladder Cancer Patients: real world data from a retrospective multicenter analysis	Giovanna Pecoraro	Received

P-264	The prognostic value of pre-neoadjuvant chemotherapy prognostic nutritional index, systemic inflammatory response index and neutrophil-to-lymphocyte ratio in muscle invasive bladder cancer	Maria Joao Ramos	Received

P-266	Gender Influence on Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer Patients	Can Aydogdu	Received

P-268	Health-related Quality of Life Outcomes in patients with Muscle Invasive Bladder Cancer after treatment: Results of a Large, Population-based, Prospective Cohort	Siberyn Nuijens	Received

15th European Multidisciplinary Congress on Urological Cancers (EMUC23)

02-05 November 2023 Marseille

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 02/11/2023 TO 02/11/2024

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access